Etiosarc: Environmental Aetiology of Sarcomas From a Multicenter French Population-based Case-control Study Among Adults
NCT03670927 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2237
Last updated 2024-11-07
Summary
Introduction: Sarcomas are rare tumors of connective tissue. The exact overall incidence of sarcomas is unknown due to diagnostic difficulties and the various histological subtypes (over 80 subtypes). However, the apparent increasing incidence of sarcomas suggests environmental causes such as pesticides. Except for some specific factors (i.e. ionizing radiation, vinyl chloride, dioxin, and genetic predispositions) the scientific knowledge on the aetiology of sarcomas is sparse and inconsistent. France is a particularly appropriate country to set up a study investigating the causes of sarcoma occurrence due to the French organization in treatment and care of sarcoma patients, which is highly structured and revolved around national expert networks. The main objective of the ETIOSARC project is to study the role of lifestyle, environmental and occupational factors in the occurrence of sarcomas among adults from a multicentric population-based case-control study.
Methods and analysis: Cases will be all incident cases (older than 18 years old) identified in 15 districts of France covered by a cancer registry and/or a reference center in sarcoma's patient care over a three-year period with an inclusion start date ranging from the 1st October 2018 to the 1st January 2020 and histologically confirmed by a second review of the diagnosis. Two controls will be individually-matched by sex, age (5-years group), and districts of residence and randomly selected from electoral list. A standardized questionnaire will be administered by a trained interviewer in order to gather information about occupational and residential history, demographic and socioeconomic characteristics and lifestyle factors. At the end of the interview, a saliva sample will be systematically proposed.
This study will permit to validate or not already suspected risk factors for sarcomas such as phenoxyherbicides, chlorophenol and to generate new hypothesis to increase our understanding about the genetic and environmental contributions in the carcinogenicity process.
Conditions
- Sarcoma
- Environmental Exposure
- Occupational Exposure
- Life Style
Interventions
- OTHER
-
Environmental, occupational and lifestyle-related exposures
A standardized questionnaire will be administered by a trained interviewer in order to gather information about occupational and residential history, demographic and socioeconomic characteristics and lifestyle factors. At the end of the interview, a saliva sample will be systematically proposed
Sponsors & Collaborators
-
Institut National de la Santé Et de la Recherche Médicale, France
lead OTHER_GOV
Principal Investigators
-
Aude Lacourt, PhD · French National Institute of Health and Medical Research
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2019-04-25
- Primary Completion
- 2024-07-03
- Completion
- 2024-07-03
Countries
- France
Study Locations
More Related Trials
-
A Prospective Non-Interventional Study in Participants Receiving Nivolumab in Adjuvant Setting for Resected Melanoma in Real-World Conditions in France
NCT04550247 ·Status: ACTIVE_NOT_RECRUITING
-
Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma
NCT01681212 ·Status: COMPLETED ·Phase: PHASE2
-
Isolated Pelvic and Limb Perfusion in the Treatment of Locally Advanced Sarcoma of Pelvis and Limbs' Girdle
NCT00181025 ·Status: UNKNOWN ·Phase: PHASE2
-
Burden and Medical Care of Sarcoma in Germany
NCT03521531 ·Status: COMPLETED
-
Structural Description of Skin Biopsies With Dynamic Full-field Optical Coherence Tomography on Suspected Basal Cell Carcinoma Lesions, a Pilot Study (DOCTOBA)
NCT05608902 ·Status: COMPLETED
-
Impact of Excision Margins on Survival and Recurrence Rate in Patients With Thick Melanoma (>2mm)
NCT02088762 ·Status: COMPLETED
-
Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE)
NCT05308966 ·Status: COMPLETED
-
QUEST: QUality of Life and Experiences of Sarcoma Trajectories
NCT03441906 ·Status: UNKNOWN
-
MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma
NCT04216953 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma
NCT07007273 ·Status: RECRUITING ·Phase: PHASE2
-
Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma
NCT02235701 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Failed First-Line Dacabazine or Temozolomide Contained Therapy
NCT02223884 ·Status: COMPLETED ·Phase: PHASE2
-
A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma
NCT01310816 ·Status: COMPLETED ·Phase: PHASE2
-
Tracing Dissemination of Melanoma Cells in Healthy Tissues
NCT02854124 ·Status: COMPLETED
-
Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma
NCT01721772 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Ultrasound Biomicroscopy in the Local Staging of Cutaneous Melanoma
NCT04702854 ·Status: RECRUITING ·Phase: NA
-
Study of Molecular Mechanisms Implicated in the Pathogenesis of Melanoma. Role of Exosomes
NCT02310451 ·Status: COMPLETED ·Phase: NA
-
Study of Core Needle Biopsy and Cryoablation of an Enlarging Tumor in Patients With Metastatic Lung Cancer and Metastatic Melanoma Receiving Post-progression Immune Checkpoint Inhibitor Therapy
NCT03290677 ·Status: COMPLETED ·Phase: NA
-
Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients
NCT04362722 ·Status: RECRUITING ·Phase: PHASE2
-
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
NCT05688280 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung
NCT00503295 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma
NCT00289016 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
NCT03567889 ·Status: RECRUITING ·Phase: PHASE3
-
Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
NCT00017121 ·Status: COMPLETED ·Phase: PHASE1
-
Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)
NCT04968106 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2